undamentalytics Newsletter
Sign in

Hedge fund

Perceptive Advisors LLC

13F for the quarter to June 30, 2026, filed August 14, 2026 · SEC CIK 1224962

Reported value
$6.4bn
94% in companies we cover
Positions we cover
95
Largest PRAX 10.6%
Copy, a year
+10.9%
S&P 500 +14.1%
Copy Sharpe ratio
0.41
S&P 500 0.78

How copying its 13F would have done

$10.0k$20.0k$40.0k 2013201520172019202120232025 $57.0k$39.4k
CopyS&P 500 $10,000 copying Perceptive Advisors LLC's filed holdings in companies we cover from August 16, 2013, buying on the first trading day after each 13F was filed and holding until the next, against the S&P 500 (total return). Marked weekly, log scale. Before costs and taxes; misses trading within each quarter and anything 13F does not show (shorts, cash, bonds, non-US holdings).

Biggest drop −75.6% (S&P 500 −31.8%); beta 1.13; alpha +1.3% a year (t = 0.15); last 12 months +13.1% against +12.1%.

Reported value by quarter

Perceptive Advisors LLC: 13F reported value Total value of all positions in each quarter's 13F, as filed (values before 2023 were filed in thousands of dollars and are converted).
$0 $1T $2T $3T $4T Reported value, 2013-06-30: $896.5M Reported value, 2013-09-30: $1.1B Reported value, 2013-12-31: $808.1M Reported value, 2014-03-31: $891.3M Reported value, 2014-06-30: $998.8M Reported value, 2014-09-30: $918.5M Reported value, 2014-12-31: $1.1B Reported value, 2015-03-31: $1.2B Reported value, 2015-06-30: $1.5B Reported value, 2015-09-30: $2.2B Reported value, 2015-12-31: $1.3B Reported value, 2016-03-31: $1.1B Reported value, 2016-06-30: $1.2B Reported value, 2016-09-30: $1.5B Reported value, 2016-12-31: $1.4B Reported value, 2017-03-31: $1.7B Reported value, 2017-06-30: $1.9B Reported value, 2017-09-30: $2.6B Reported value, 2017-12-31: $3B Reported value, 2018-03-31: $3.5B Reported value, 2018-06-30: $3.8B Reported value, 2018-09-30: $3.7B Reported value, 2018-12-31: $2.6B Reported value, 2019-03-31: $3.5B Reported value, 2019-06-30: $4.3B Reported value, 2019-09-30: $3.7B Reported value, 2019-12-31: $5B Reported value, 2020-03-31: $3.8B Reported value, 2020-06-30: $5.3B Reported value, 2020-09-30: $5.9B Reported value, 2020-12-31: $8.5B Reported value, 2021-03-31: $6.7B Reported value, 2021-06-30: $13.8B Reported value, 2021-09-30: $6B Reported value, 2021-12-31: $11.3B Reported value, 2022-03-31: $4.4B Reported value, 2022-06-30: $2.7B Reported value, 2022-09-30: $3.4B Reported value, 2022-12-31: $3.5T Reported value, 2023-03-31: $3.4B Reported value, 2023-06-30: $3.4B Reported value, 2023-09-30: $3B Reported value, 2023-12-31: $4.5B Reported value, 2024-03-31: $5.7B Reported value, 2024-06-30: $4.1B Reported value, 2024-09-30: $4.7B Reported value, 2024-12-31: $3.6B Reported value, 2025-03-31: $2.8B Reported value, 2025-06-30: $2.7B Reported value, 2025-09-30: $3.4B Reported value, 2025-12-31: $5.4B Reported value, 2026-03-31: $5B Reported value, 2026-06-30: $6.4B 2013-06-30 2016-03-31 2018-12-31 2021-09-30 2026-06-30 $6.4B
View chart data
Period Reported value
2013-06-30 $896.5M
2013-09-30 $1.1B
2013-12-31 $808.1M
2014-03-31 $891.3M
2014-06-30 $998.8M
2014-09-30 $918.5M
2014-12-31 $1.1B
2015-03-31 $1.2B
2015-06-30 $1.5B
2015-09-30 $2.2B
2015-12-31 $1.3B
2016-03-31 $1.1B
2016-06-30 $1.2B
2016-09-30 $1.5B
2016-12-31 $1.4B
2017-03-31 $1.7B
2017-06-30 $1.9B
2017-09-30 $2.6B
2017-12-31 $3B
2018-03-31 $3.5B
2018-06-30 $3.8B
2018-09-30 $3.7B
2018-12-31 $2.6B
2019-03-31 $3.5B
2019-06-30 $4.3B
2019-09-30 $3.7B
2019-12-31 $5B
2020-03-31 $3.8B
2020-06-30 $5.3B
2020-09-30 $5.9B
2020-12-31 $8.5B
2021-03-31 $6.7B
2021-06-30 $13.8B
2021-09-30 $6B
2021-12-31 $11.3B
2022-03-31 $4.4B
2022-06-30 $2.7B
2022-09-30 $3.4B
2022-12-31 $3.5T
2023-03-31 $3.4B
2023-06-30 $3.4B
2023-09-30 $3B
2023-12-31 $4.5B
2024-03-31 $5.7B
2024-06-30 $4.1B
2024-09-30 $4.7B
2024-12-31 $3.6B
2025-03-31 $2.8B
2025-06-30 $2.7B
2025-09-30 $3.4B
2025-12-31 $5.4B
2026-03-31 $5B
2026-06-30 $6.4B

Holdings and moves

CompanyShare of portfolioValueSharesChange in shares
PRAXPraxis Precision Medicines, Inc.10.61%$681.6m2.04M0.0%
SYRESpyre Therapeutics, Inc.5.97%$383.5m4.32M+14.2% Added
CELCCelcuity Inc.5.21%$334.5m3.20M+2.2% Added
ASNDAscendis Pharma A/s4.83%$310.4m1.16MNew
RYTMRhythm Pharmaceuticals, Inc.4.47%$287.2m2.59M+9.0% Added
ROIVRoivant Sciences Ltd.4.45%$286.1m8.09M−2.4% Reduced
RLAYRelay Therapeutics, Inc.4.11%$263.9m14.11M+44.7% Added
TVTXTravere Therapeutics, Inc.3.32%$213.2m3.75M−9.4% Reduced
KARDKardigan, Inc.3.04%$195.6m8.20MNew
EWTXEdgewise Therapeutics, Inc.2.77%$177.7m4.37M−1.1% Reduced
AMLXAmylyx Pharmaceuticals, Inc.2.33%$149.7m8.33M+0.6% Added
MGTXMeiragtx Holdings plc2.27%$145.7m10.79M+4.5% Added
ORKAOruka Therapeutics, Inc.1.99%$128.0m1.35M−3.6% Reduced
INBXInhibrx Biosciences, Inc.1.91%$123.0m1.30M−10.0% Reduced
PTGXProtagonist Therapeutics, Inc1.87%$120.4m981.9K−20.2% Reduced
SLDBSolid Biosciences Inc.1.85%$118.9m11.91M0.0%
ZYMEZymeworks Inc.1.70%$109.3m4.18M+19.2% Added
TNGXTango Therapeutics, Inc.1.64%$105.6m3.38M+317.9% Added
IMTXImmatics N.V.1.64%$105.2m10.38M0.0%
NRIXNurix Therapeutics, Inc.1.63%$104.8m4.32M+16.4% Added
BCRXBiocryst Pharmaceuticals Inc1.60%$103.1m10.31M+38.7% Added
RVMDRevolution Medicines, Inc.1.54%$98.8m527.6K+104.0% Added
AVLNAvalyn Pharma Inc.1.37%$88.1m2.68MNew
DYNDyne Therapeutics, Inc.0.93%$59.7m2.69M−42.4% Reduced
BIIBBiogen0.93%$59.7m276.2KNew
IMVTImmunovant, Inc.0.81%$52.3m1.36M−15.0% Reduced
UNHUnitedHealth Group0.76%$48.5m116.8KNew
IONSIonis Pharmaceuticals Inc0.70%$44.9m566.0K+12.3% Added
STROSutro Biopharma, Inc.0.67%$43.3m1.30M+82.4% Added
ANROAlto Neuroscience, Inc.0.66%$42.5m1.61M−19.9% Reduced
JAZZJazz Pharmaceuticals plc0.64%$41.0m170.0K0.0%
CRVSCorvus Pharmaceuticals, Inc.0.62%$39.9m2.67M+16.4% Added
SIONSionna Therapeutics, Inc.0.62%$39.8m905.0K+37.4% Added
CTMXCytomx Therapeutics, Inc.0.61%$39.1m10.44M+3.4% Added
AORTArtivion, Inc.0.61%$39.0m1.74M+6.1% Added
XFORX4 Pharmaceuticals, Inc0.58%$37.0m7.93M+17.7% Added
CORTCorcept Therapeutics Inc0.54%$34.6m398.4K+696.8% Added
RGENRepligen Corp0.53%$33.9m248.2K−11.5% Reduced
AVRAnteris Technologies Global Corp.0.53%$33.7m3.43M0.0%
RAPPRapport Therapeutics, Inc.0.50%$32.2m773.3K+14.8% Added
CRLCharles River Laboratories0.49%$31.8m140.0KNew
AXSMAxsome Therapeutics, Inc.0.45%$29.0m118.5K−21.0% Reduced
DBVTDBV Technologies S.a.0.42%$27.1m1.65M+71.4% Added
IRTCIrhythm Holdings, Inc.0.41%$26.6m223.8K+113.1% Added
ADPTAdaptive Biotechnologies Corp0.41%$26.1m1.22M+698.2% Added
SABSSAB Biotherapeutics, Inc.0.40%$25.8m6.63M+3.0% Added
DHRDanaher Corporation0.39%$24.8m130.0KNew
TENXTenax Therapeutics, Inc.0.39%$24.7m1.70M+17.4% Added
NAUTNautilus Biotechnology, Inc.0.34%$21.8m11.63M−7.6% Reduced
OBIOOrchestra Biomed Holdings, Inc.0.34%$21.7m5.04M0.0%
ISRGIntuitive Surgical0.32%$20.6m51.9K−39.3% Reduced
ANLAdlai Nortye Group Ltd.0.32%$20.6m1.79MNew
CTNMContineum Therapeutics, Inc.0.32%$20.6m1.26M0.0%
NVCTNuvectis Pharma, Inc.0.29%$18.4m1.00MNew
PALIPalisade BIO, Inc.0.27%$17.6m8.43M−5.6% Reduced
OMDAOmada Health, Inc.0.27%$17.3m786.3K0.0%
LONALeonabio, Inc.0.27%$17.1m1.86M0.0%
EOLSEvolus, Inc.0.27%$17.1m2.46M+91.1% Added
IVVDInvivyd, Inc.0.25%$16.1m18.49M−11.4% Reduced
MIRMMirum Pharmaceuticals, Inc.0.21%$13.5m115.4KNew
SRZNSurrozen, Inc.0.20%$13.1m504.0K+119.7% Added
BBNXBeta Bionics, Inc.0.20%$13.1m832.9K−1.2% Reduced
AXGNAxogen, Inc.0.18%$11.4m247.3K−64.5% Reduced
OSCROscar Health, Inc.0.18%$11.4m400.0KNew
OCSOculis Holding AG0.17%$11.2m808.8K+63.8% Added
SPTXSeaport Therapeutics, Inc.0.17%$10.9m500.0KNew
VRDNViridian Therapeutics, Inc.\de0.17%$10.7m582.0K−50.3% Reduced
BSXBoston Scientific0.17%$10.7m250.0KNew
BLLNBilliontoone, Inc.0.16%$10.4m86.8K−5.4% Reduced
ABVXAbivax S.a.0.15%$9.9m74.0K−77.5% Reduced
NTRANatera, Inc.0.15%$9.4m34.7KNew
ENGNEngene Therapeutics Inc.0.13%$8.3m4.82MNew
RACCResearch Alliance Corp III0.13%$8.0m750.0KNew
AGMBAgomab Therapeutics NV0.12%$7.8m600.0K0.0%
CGEMCullinan Therapeutics, Inc.0.12%$7.8m426.5KNew
QUREUniqure N.V.0.12%$7.7m168.0KNew
MOBIMobia Medical, Inc.0.11%$7.0m523.7KNew
ADGMAdagio Medical Holdings, Inc.0.10%$6.4m9.88M0.0%
GHGuardant Health, Inc.0.10%$6.2m41.3K−86.2% Reduced
PHATPhathom Pharmaceuticals, Inc.0.09%$5.8m532.0K−42.5% Reduced
OTLKOutlook Therapeutics, Inc.0.08%$5.0m3.14MNew
COGTCogent Biosciences, Inc.0.07%$4.7m121.1K0.0%
EDSAEdesa Biotech, Inc.0.07%$4.6m563.2K0.0%
AVTXAvalo Therapeutics, Inc.0.06%$4.1m219.8K+57.4% Added
TWSTTwist Bioscience Corp0.06%$3.8m36.8K−75.5% Reduced
CBIOCrescent Biopharma, Inc.0.06%$3.7m206.9K0.0%
XERSXeris Biopharma Holdings, Inc.0.06%$3.7m467.0KNew
OMOutset Medical, Inc.0.06%$3.6m833.3K0.0%
BDSXBiodesix Inc0.04%$2.5m108.7KNew
CNTBConnect Biopharma Holdings Ltd0.03%$1.9m792.7K0.0%
MDLNMedline Inc.0.02%$1.1m28.0K0.0%
ADMAAdma Biologics, Inc.0.01%$952,213113.8K−75.7% Reduced
CPIXCumberland Pharmaceuticals Inc0.01%$628,44397.0K−50.8% Reduced
XGNExagen Inc.0.01%$534,252114.9K0.0%
ENSCEnsysce Biosciences, Inc.0.00%$25,13386.7K0.0%
CompanyBought (value)Shares
ASNDAscendis Pharma A/s$310.4m1.16M
KARDKardigan, Inc.$195.6m8.20M
AVLNAvalyn Pharma Inc.$88.1m2.68M
RLAYRelay Therapeutics, Inc.$81.5m4.36M
TNGXTango Therapeutics, Inc.$80.3m2.57M
BIIBBiogen$59.7m276.2K
RVMDRevolution Medicines, Inc.$50.4m269.0K
UNHUnitedHealth Group$48.5m116.8K
SYRESpyre Therapeutics, Inc.$47.6m536.3K
CRLCharles River Laboratories$31.8m140.0K
CORTCorcept Therapeutics Inc$30.3m348.4K
BCRXBiocryst Pharmaceuticals Inc$28.7m2.87M
DHRDanaher Corporation$24.8m130.0K
RYTMRhythm Pharmaceuticals, Inc.$23.6m212.5K
ADPTAdaptive Biotechnologies Corp$22.8m1.06M

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanySold (value)Shares
DYNDyne Therapeutics, Inc.−$44.0m−1.98M
GHGuardant Health, Inc.−$38.8m−258.7K
ABVXAbivax S.a.−$34.0m−254.9K
PTGXProtagonist Therapeutics, Inc−$30.5m−249.0K
DRUGBright Minds Biosciences Inc.−$27.5m−377.5K
BLTEBelite BIO, Inc−$24.2m−152.0K
TVTXTravere Therapeutics, Inc.−$22.2m−390.0K
AXGNAxogen, Inc.−$20.8m−450.0K
INBXInhibrx Biosciences, Inc.−$13.7m−144.9K
ISRGIntuitive Surgical−$13.3m−33.5K
TWSTTwist Bioscience Corp−$11.6m−113.2K
VRDNViridian Therapeutics, Inc.\de−$10.8m−588.8K
ANROAlto Neuroscience, Inc.−$10.6m−400.0K
EVMNEvommune, Inc.−$10.3m−448.4K
NMRANeumora Therapeutics, Inc.−$10.0m−5.10M

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanyValue last quarterShares
DRUGBright Minds Biosciences Inc.$27.5m377.5K
BLTEBelite BIO, Inc$24.2m152.0K
EVMNEvommune, Inc.$10.3m448.4K
NMRANeumora Therapeutics, Inc.$10.0m5.10M
NBIXNeurocrine Biosciences Inc$8.6m65.0K
IRDOpus Genetics, Inc.$8.4m1.84M
IKTInhibikase Therapeutics, Inc.$3.9m2.31M
PTNPalatin Technologies Inc$1.1m61.9K
  • Health Care100.0%

Share of the value held in companies we cover, by sector.

PeriodCopy, a yearS&P 500SharpeS&P 500Biggest dropBeta
Whole backtestAugust 16, 2013 to November 2, 2026+10.9%+14.1%0.410.78−75.6%1.13
2018 onwardsJanuary 5, 2018 to November 2, 2026+3.4%+13.9%0.190.66−75.6%1.10
Last three yearsNovember 3, 2023 to November 2, 2026+23.3%+21.8%0.661.16−47.5%1.31
Last yearNovember 7, 2025 to November 2, 2026+21.2%+14.2%0.650.84−23.7%1.13

From SEC Form 13F data sets. A 13F lists long positions in US-listed shares at the quarter's end, filed up to 45 days later; it does not show shorts, cash, bonds, non-US holdings or trades within the quarter. Positions in companies outside our coverage are not listed here. Research, not investment advice.